USPTO serial 79307004
RHEACELL INNOVATIVE STEM CELL THERAPIES
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 12, 2022
- Examiner
- OSGOOD, KRYSTINA E
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with RHEACELL INNOVATIVE STEM CELL THERAPIES?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Sean K. Owens
Sean K. Owens Wood Herron & Evans LLP441 Vine Street, Suite 2700Cincinnati, OH 45202UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Drugs, namely, drug delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceuticals; pharmaceutical and veterinary preparations for the treatment of skin diseases, pharmaceutical and veterinary preparations for the treatment of vertigo, pharmaceutical and veterinary preparations for the treatment of nausea, pharmaceutical and veterinary preparations for the treatment of vomiting, pharmaceutical and veterinary preparations for the treatment of migraine, pharmaceutical and veterinary preparations for the treatment of disease and disorders of the respiratory system, the gastrointestinal system, the endocrine system, the cardiovascular system, the nervous system, the musculoskeletal system, the urinary system, the integumentary system, and the reproductive system, pharmaceutical and veterinary preparations for the treatment of blood diseases and disorders, pharmaceutical and veterinary preparations, namely, antibiotics, immune suppressants, anti-inflammatory preparations, pharmaceutical and veterinary preparations for wound healing, pharmaceutical and veterinary preparations for anti-aging, namely, stem cells for medical and medical aesthetic purposes, fibroblast cells for medical and medical aesthetic purposes, surgical tissue implants comprised of living tissues obtained from fibroblasts; diagnostic agents for medical purposes; diagnostic preparations for medical and biomedical purposes; pharmaceutical cell preparations for medical use for the treatment of skin diseases, vertigo, nausea, vomiting, migraine, disease and disorders of the respiratory system, disease and disorders of the gastrointestinal system, disease and disorders of the endocrine system, disease and disorders of the cardiovascular system, disease and disorders of the nervous system, disease and disorders of musculoskeletal system, disease and disorders of urinary system, disease and disorders of integumentary system, disease and disorders of the reproductive system, blood diseases and disorders; sterilizing substances for medical use; sterilizing substances for biomedical purposes; live implants comprising of live tissues for pharmaceutical purposes; biochemical and chemical products, namely, biochemical preparations for the treatment of skin diseases and chemical reagents for medical use; biochemical and chemical products, namely, biochemical preparations for the treatment of skin diseases and chemical reagents for pharmaceutical purposes; biochemical and chemical products for pharmaceutical or medical purposes, namely, biochemical preparations for the treatment of skin diseases, vertigo, nausea, vomiting, migraine, disease and disorders of the respiratory system, disease and disorders of the gastrointestinal system, disease and disorders of the endocrine system, disease and disorders of the cardiovascular system, disease and disorders of the nervous system, disease and disorders of musculoskeletal system, disease and disorders of urinary system, disease and disorders of integumentary system, and disease and disorders of the reproductive system, blood diseases and disorders for diagnostic purposes; proteins being protein supplements for medical purposes; biological preparations for medical and veterinary purposes, and pharmaceutical and veterinary preparations, all for external use for the treatment of skin diseases, wounds, ulcers, burns and surgical wounds; biological, pharmaceutical and veterinary preparations for skin care for medical purposes; medical dressings; pharmaceutical preparations for wound treating and healing; biological, pharmaceutical and veterinary preparations for the treatment of chronic wounds, ulcers, burns and surgical wounds; stem cells for medical purposes; stem cells for veterinary purposes; stem cells for aesthetic purposes for medical use; somatic stem cell therapeutics for medical purposes; pharmaceutical implants, namely, implantable surgery human allograft bones, biological bone tissue grafts, cells for medical use, biological bone marrow tissue; surgical implants comprised of living stem cells; surgical implants comprised of living fibroblasts tissue cells; biological human skin and bone tissue intended for subsequent implantation; cell growth media for culturing cells for medical purposes; pharmaceutical preparations for tissue regeneration; vascular grafts; living tissue, namely, vascular grafts; biotechnologically engineered tissue products, namely, tissue cells in sheet form and plasters for wound healing and treating burns for medical purposes, biological eye lens tissue grafts, biological bone tissue grafts | ACTIVE | — |
| 042 | Pharmaceutical drug development; scientific and technological services, namely medical and pharmaceutical research services and technical research in the field of pharmaceutical studies, regenerative medicine and tissue engineering; research and development services in the fields of cell diagnostics and research and development services relating to new products for others in the field of therapy and surgical and medical instruments; industrial analysis and research services, namely analysis of industrial fluids and medical research, chemical analysis; scientific research for medical purposes in the field of stem cell therapies; stem cell research; scientific and medical research and development in the field of stem cells; scientific research, testing and analysis services of the services of others to determine conformity with certification standards and in the field of regenerative medicine and tissue engineering; scientific research for medical purposes; medical research; research in the field of biotechnology; research in the field of gene therapy; research and development in the field of immunology; research and development in the field of antibodies; research and development in the field of antibody technology; research and development in the field of bacteriology; product research and development in the field of gene expression systems; research and development in the field of vaccines; research and development services for the pharmaceutical industry; research and development services in the field of biotechnology | ACTIVE | — |
| 044 | Medical services; medical diagnostic services for carrying out tests and analyses; medical assistance; medical clinic services; hospital services; plastic and cosmetic surgery; medical therapies, namely, stem cell therapy for treating medical conditions; medical services being human cells and tissue banks, stem cell banks and bone marrow banks, medical services in the field of regenerative medicine and medical analysis services relating to the treatment of patients in the field of tissue engineering; medical services being banks of human tissue and stem cells, medical services in the field of regenerative medicine and medical analysis services relating to the treatment of patients in the field of tissue engineering; medical services in the nature of stem cell banks for medical transplantation; medical services in the nature of cultured stem cell banks for medical transplantation | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by RHEACELL GmbH & Co. KG
- Other trademarks owned by RHEACELL GmbH & Co. KG
- Other trademarks owned by RHEACELL GmbH & Co. KG
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named RHEACELL INNOVATIVE STEM CELL THERAPIES
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 14, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Sep 20, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Aug 26, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Aug 26, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 12, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 12, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 25, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 25, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 22, 2022 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jan 5, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 5, 2022 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jan 5, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 21, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 21, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 21, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 21, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 21, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 7, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 6, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 6, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 28, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 9, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 9, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 8, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 7, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 3, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 26, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 22, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 18, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |